Rituximab for treating inhibitors in people with inherited severe hemophilia.

ABSTRACT:

Background

Hemophilia A and B are inherited coagulation disorders characterized by a reduced or absent level of factor VIII or factor IX respectively. The severe form is characterized by a factor level less than 0.01 international units (IU) per milliliter. The development of inhibitors in hemophilia is the main complication of treatment, because the presence of these antibodies, reduces or even nullifies the efficacy of replacement therapy, making it very difficult to control the bleeding. People with inhibitors continue to have significantly higher risks of morbidity and mortality, with considerable treatment costs. Given the wide 'off-label' use of rituximab for treating people with hemophilia and inhibitors, its efficacy and safety need to be evaluated. This is an update of a p

SUBMITTER: Jiang L 

PROVIDER: S-EPMC8407108 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature